TY - JOUR
T1 - Beyond the cell
T2 - novel noncellular immunotherapy approaches to multiple myeloma
AU - Holstein, Sarah A.
N1 - Publisher Copyright:
© 2022 by The American Society of Hematology.
PY - 2022/12/9
Y1 - 2022/12/9
N2 - The development of novel cellular therapies and bispecific T-cell-engaging antibodies is occurring at breakneck speed in multiple myeloma (MM). While groundbreaking, these agents have their unique logistical and toxicity issues and currently do not represent a curative approach. In this context, there continues to be an urgent need to develop novel, off-the-shelf immunotherapy approaches to add to the armamentarium. This article explores novel agents being investigated in combination with standard immunomodulatory drugs as well as next-generation cereblon E3 ligase modulators. These novel agents include drugs being repurposed from their use in other diseases as well as novel monoclonal antibodies. In addition, agents under development such as immunocytokines, immunotoxins, and natural killer-cell activators/engagers are reviewed. These novel therapeutic strategies hold the promise of countermanding the immunosuppressive tumor microenvironment, leading to enhanced anti-MM activity.
AB - The development of novel cellular therapies and bispecific T-cell-engaging antibodies is occurring at breakneck speed in multiple myeloma (MM). While groundbreaking, these agents have their unique logistical and toxicity issues and currently do not represent a curative approach. In this context, there continues to be an urgent need to develop novel, off-the-shelf immunotherapy approaches to add to the armamentarium. This article explores novel agents being investigated in combination with standard immunomodulatory drugs as well as next-generation cereblon E3 ligase modulators. These novel agents include drugs being repurposed from their use in other diseases as well as novel monoclonal antibodies. In addition, agents under development such as immunocytokines, immunotoxins, and natural killer-cell activators/engagers are reviewed. These novel therapeutic strategies hold the promise of countermanding the immunosuppressive tumor microenvironment, leading to enhanced anti-MM activity.
UR - http://www.scopus.com/inward/record.url?scp=85143917321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143917321&partnerID=8YFLogxK
U2 - 10.1182/hematology.2022000335
DO - 10.1182/hematology.2022000335
M3 - Article
C2 - 36485098
AN - SCOPUS:85143917321
SN - 1520-4391
VL - 2022
SP - 173
EP - 179
JO - Hematology. American Society of Hematology. Education Program
JF - Hematology. American Society of Hematology. Education Program
IS - 1
ER -